Company Listing
Syntaxin

Syntaxin genetically engineered bacterial toxins to develop novel drugs that inhibit abnormal cell secretion, a key component of many diseases. The company was focused on the treatment of neurological, inflammatory and endocrine diseases. Syntaxin was formed as a spin-out from the UK Health Protection Agency in November 2005. The company was acquired by Ipsen in July 2013.

BACK
Location
Abingdon, UK

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Syntaxin genetically engineered bacterial toxins to develop novel drugs that inhibit abnormal cell secretion, a key component of many diseases. The company was focused on the treatment of neurological, inflammatory and endocrine diseases. Syntaxin was formed as a spin-out from the UK Health Protection Agency in November 2005. The company was acquired by Ipsen in July 2013.

Location
Abingdon, UK
BACK
 
Copyright Abingworth 2017